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Abstract
In the presence of different environmental cues that are able to trigger specific responses, a given genotype has
the ability to originate a variety of different phenotypes. This property is defined as plasticity and allows cell fate
definition and tissue specialization. Fundamental epigenetic mechanisms drive these modifications in gene
expression and include DNA methylation, histone modifications, chromatin remodeling, and microRNAs.
Understanding these mechanisms can provide powerful tools to switch cell phenotype and implement cell therapy.
Environmentally influenced epigenetic changes have also been associated to many diseases such as cancer and
neurodegenerative disorders, with patients that do not respond, or only poorly respond, to conventional therapy. It
is clear that disorders based on an individual’s personal genomic/epigenomic profile can rarely be successfully
treated with standard therapies due to genetic heterogeneity and epigenetic alterations and a personalized
medicine approach is far more appropriate to manage these patients.
We here discuss the recent advances in small molecule approaches for personalized medicine, drug targeting, and
generation of new cells for medical application. We also provide prospective views of the possibility to directly
convert one cell type into another, in a safe and robust way, for cell-based clinical trials and regenerative medicine.
Keywords: Epigenetic conversion, Epigenetics, iPSCs, Molecular medicine, Personalized medicine, Regenerative
medicine, Small molecules
Background
Epigenetics is at the center of modern biology and medi-
cine, since it is currently considered a fundamental tool to
understand embryo development and stem cell biology, as
well as to explain the relationship among an individual’s
genetic background, the environmental influences, aging,
and disease susceptibility.
The most exciting idea is that epigenetics may provide
new clues to intervene at the junction between the gen-
ome and the environment, modifying the effects of dele-
terious genes [1]. It would be also useful to develop new
strategies for disease prevention and therapy and to mas-
ter tissue reprogramming in regenerative medicine.
In particular, during the last years, great attention was
given to epigenetics in order to prevent, diagnose, and treat
different diseases. Indeed, it has been demonstrated that
malignant transformations as well as several disorders, such
as autism, bipolar disorder, familial hypertrophic cardiomy-
opathy, schizophrenia, and syndromes, namely Prader-
Willi, Angelman, Beckwith-Wiedemann, and Silver-Russell,
are directly or indirectly caused by epigenetic alterations in
form of mutation of DNA methylation or incorrect histone
modifications [2–5]. In particular, DNA methyltransferase
(DNMT) inhibiting nucleoside analogs, non-nucleoside an-
alogs, and histone deacetylase (HDAC) inhibitors have been
proposed as potential anti-cancer drugs. In parallel, several
researches are focusing on the development of direct dis-
ease treatments with small molecules, based on individual
personal genomic profile and epigenetic characteristics of
each patient, in order to improve outcomes.
Presently, a growing problem is also represented by
degenerative diseases that, despite decades of research,
still lack effective cures. Regenerative medicine has
earned increased attention and represents an attractive
option as a potentially novel approach for the treatment
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of neurodegenerative, cardiovascular and liver diseases,
diabetes, spinal cord injury, and corneal degeneration.
In this field, the use of small molecules in cell repro-
gramming technology has allowed for the development
of protocols that avoid the use of retroviral and/or len-
tiviral vectors, and the insertion of transgenes for the
generation of induced pluripotent cells (iPSC). How-
ever, although these cells may represent a promising
stem cell source, the induction of a stable pluripotent
state and the deriving cell instability severely limits
their use in cell therapy.
In order to circumvent these limits, a new small-
molecule-based method able to directly convert a ter-
minally differentiated cell into a different cell type has
been recently proposed. This new approach demon-
strated that it is possible to dynamically interact with
cell genotype and phenotype through the use of epi-
genetic modifiers [2–7].
We here discuss the recent advances in small molecule
approaches for drug targeting, personalized medicine, and
generation of new cells for medical application. We also
provide prospective views on the possibility to directly con-
vert one cell type into another, in a safe and reproducible
way, in order to obtain cells that may find application in
clinical trials and regenerative medicine.
Review
Molecular basis of epigenetics
The molecular basis of epigenetics is a complex
phenomenon that determines activation or silencing of
certain genes, without changing the DNA sequence.
There are several types of epigenetic mechanisms that
play an essential role in the regulation of chromatin struc-
ture and gene expression, namely histone post-translational
modifications, covalent modification of DNA, small (21- to
26-nt) non-coding RNAs (ncRNAs), and recombination of
non-genic DNA.
These processes are driven by different proteins that are
usually categorized based on their molecular nature. In
particular, the enzymes involved in epigenetic control are
classified as epigenetic writers, epigenetic erasers, and epi-
genetic readers (see Table 1).
The firsts catalyze modifications either on DNA, RNA,
or histone proteins by adding of chemical groups on top
of them. This group includes the following:
Table 1 Mechanisms involved in epigenetic control and related epigenetic enzymes. References
Mechanism Writer Eraser Reader
DNA methylation DNA methyltransferases
(DNMT1, DNMT3) [67, 68]
DNA demethylation enzymes (TET) [69] Methyl-CpG binding domains
(MECP2, MBD1, MBD2, and MBD4) [70]
Histone lysine acetylation Histone acetyltransferases
(GCN5/PCAF, MYST, P300/
CBP, SRC/p160) [71]
Histone deacetylases (HDAC1, HDAC2,
HDAC3, HDAC4, HDAC5, HDAC6, HDAC7,
HDAC8, HDAC9, HDAC10, HDAC11); Sir2-
like proteins (SIRT1, SIRT2, SIRT3, SIRT4,
SIRT5, SIRT6, SIRT7) [72]
Bromodomain, tandem PHD [73, 74]
Histone arginine
methylation
Histone arginine methyltransferases
(PRMT1, PRMT2, PRMT3, PRMT5,
PRMT6, PRMT7, CARM1) [75]
Histone arginine demethylase (bifunctional
arginine demethylase and lysyl-hydroxylase
JMJD6) [76]
Tudor, ADD, WD40 [73, 74]
Histone lysine methylation Histone lysine methyltransferases
(EZH, SET1, SET2, SMYD, SUV39,
SUV4-20, RIZ, SET8/PR-SET7,
SET7/9, PRDM) [77]
Histone lysine demethylases
Lysine-specific demethylase (LSD1, LSD2);
Jumonji histone demethylases (JHDM1,
JHDM2, JHDM3/JMJD2, JARID, JMJC,
PHF2/PHF8, UTX/UTY) [77]
Chromodomain, ADD, ankyrin, BAH,
chromobarrel
Tudor, PHD fingers, MBT, ZF-CW,
WD40, PWWP [73, 74]
Histone phosphorylation Histone kinases (AGC, CaMK,
CMGC, protein-tyrosine
kinase, MEK) [78]
Histone phosphatases
Serine/threonine phosphatases (PPP,
PPM); tyrosine phosphatases (PTP, VH1-
like dual-specificity phosphatase,
cdc25) [79, 80]
Chromoshadow, 14.3.3 proteins, BIR,
BRCT [73, 74]
Histone lysine
ubiquitination
Histone lysine ubiquitinases
(E1 enzyme, E2 ubiquitin
conjugases); E3 ubiquitin-
protein ligases (HECT domain,
RING finger domain) [81]
Histone lysine deubiquitinases
(UCH, USP, MJD, OTU, JAMM) [82]
Unknown
Histone arginine
citrullination
Histone arginine deiminases
(PAD1, PAD2, PAD3, PAD4,
PAD6) [83]
Unknown Unknown
Histone lysine biotinylation Histone lysine biotinases
(HLCS) [84]
Unknown Unknown
Histone lysine ribosylation Histone lysine ribosylases
(PARP1) [85]
Histone lysine deribosylase
(PARG) [85]
Unknown
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– Histone methyltransferases (HMTs), which are
further subdivided into lysine methyltransferases
(PKMTs) and arginine methyltransferases (PRMTs)
according to their target residue
– Histone acetyltransferases (HATs)
– Enzymes that catalyze the phosphorylation of
histone tails
– Ubiquitin-conjugating enzymes
– DNA methyltransferases (DNMTs)
In contrast, epigenetic erasers remove the structural
modifications introduced by the writers. They comprise
the following:
– Histone deacetylases (HDACs)
– Histone serine/threonine/tyrosine phosphatases
– Histone deubiquitinases (DUBs)
– Histone lysine/arginine demethylases
– DNA demethylation enzymes
Lastly, epigenetic readers are effector proteins that
recognize specific structural units in nucleic acids and
proteins and are recruited to specific marks on histones
or nucleotides. Their structure is characterized by a cav-
ity in which to accommodate a specific epigenetic mark.
The interaction between the reader domain and the modi-
fied amino acid allows to distinguish similar epigenetic
marks. Furthermore, they can be also contained in writer
or eraser enzymes and are classified into four groups:
– Chromatin architectural proteins
– Chromatin remodeling enzymes
– Chromatin modifiers
– Adaptor proteins
Epigenetic in medicine
During the last years, the understanding of genetic and epi-
genetic is becoming increasingly important for the preven-
tion, diagnosis, and treatment of several diseases, and much
attention has been given to molecular medicine. In this con-
test, it has been demonstrated that several disorders were
directly or indirectly caused by epigenetic modifications in
form of impaired DNA methylations or incorrect his-
tone modifications [8]. Human diseases, such as autism,
bipolar disorder, diabetes, familial hypertrophic cardiomy-
opathy, schizophrenia, and syndromes, namely Prader-Willi,
Angelman, Beckwith-Wiedemann, and Silver-Russell, have
been related to alteration of DNA methylation and modifi-
cations of normal imprinting patterns [9–11]. In particular,
these human rare syndromes appear to be directly linked to
aberrant expression of long ncRNAs [12]. They are involved
in the epigenetic controls of coding genes, through the up-
or down-regulation of messenger RNAs (mRNAs), methyla-
tion, and transcription of specific gene polymorphisms [13],
thus exerting a powerful effect on a number of physiological
processes. Their aberrant levels are likely to cause disorders
associated with protein dysregulations [14]. Despite the
present advances, regulatory mechanisms and functions of
long non-coding RNA (lncRNA), and their association with
the majority of the diseases, need to be further elucidated in
order to improve patient management, as well as the pre-
vention and treatment of the related genetic diseases.
It is well known that genetic aberrations can also pro-
mote malignant transformations. Many studies demon-
strated that initiation and progression of several form of
cancer are related to epigenetic aberrations that alter the
complex functional interaction and balance between onco-
genes and tumor suppressor genes [15, 16]. One of the
main actors is hypermethylation of many tumor suppressor
genes, such as those involved in DNA repair (BRCA1,
MGMT and MLH1), signal transduction (RASSF1A), cell
cycle regulation (p16INK4a), apoptosis (DAPK and TMS1),
and angiogenesis (THBS1) [17–19]. Indeed, epigenetic dis-
ruption was one of the main abnormality identified in can-
cer cells [20] and might lead to gene activation, promoting
overexpression of oncogenes, and might represents a fun-
damental mechanism of cancer development [17].
Alteration of normal patterns of covalent histone modi-
fications is yet another hallmark of cancer. The most char-
acteristic examples are, in this respect, related to the
overexpression, mutations, and/or chromosomal translo-
cations of histone acetylation/deacetylation (HAT/HDAC)
and methylation/demethylation (HMT/HDM or sirtuins)
enzymes [21].
In this context, the development of molecular medicine,
the fast progress of the new epigenetic approaches, and the
reversible nature of the epigenome offer great advances in
the fields of drug targeting and personalized medicine.
Based on these observations, DNMT-inhibiting cytosine
nucleoside analogs and non-nucleoside analogs (see Table 2)
Table 2 List of nucleoside and non-nucleoside analog DNMT
inhibitors
Nucleoside analogs Non-nucleoside analogs
5-6-Dihydro-azacytidine (−)-Epigallocatechin-3-galate
5-Fluoro-2-deoxycytidine Curcumin
Azacytidine Mithramycin A
CP-4200 Nanomycin A
Decitabine Natural compounds: flavonoids
NPEOC-DAC NSC-106084
SGI-110 NSC-14778
Zebularine PRIMA-1
Psammaplin A
RG-108
SGI-1027
Synthetic compounds: procaine
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have been proposed as potential anti-cancer drugs. The most
characterized nucleoside analogs, 5-azacytidine (Vidaza®) and
5-aza-2′-deoxycytidine or decitabine (Dacogen®), have been
approved by the US Food and Drug Administration (FDA)
and European Medicines Agency (EMA) for the treatment
of myelodysplastic syndrome (MDS) and chronic myelomo-
nocytic leukemia (CMML). Several clinical studies have also
shown promising results in patients with acute myeloid
leukemia (AML) and acute lymphoblastic leukemia
(ALL) [22]. Preliminary experiments also demonstrated
that dihydro-5-azacytidine (DHAC) and zebularine are
less cytotoxic than the 5-aza-nucleosides in cultured
cells and that are able to inhibit tumorigenesis in vari-
ous cancer cell lines [23–27]. However, further studies
are needed in order to demonstrate safety and efficacy
and, eventually, enter into the clinical phase.
Non-nucleoside analogs are also being studied. For
instance, procainamide and its analog procaine have
shown DNMT inhibitory effects in various cancer types, as
well as other synthetic compounds, such as RG108, MG98,
PRIMA-1, and SGI-1027, and natural compounds, namely
flavonoids, psammaplin A, and curcumin. However, none
of them have entered clinical development yet, since there
is still a long way to go before we may obtain the identifica-
tion of novel, selective, non-nucleoside DNMT inhibitors.
As described above, cancer cells can also be characterized
by alterations of histone methyltransferases/demethylases
and overexpression of histone deacetylases (HDACs). Sev-
eral reports indicate that HDAC inhibitors are able to in-
duce a cell cycle arrest at G1 or G2-M stage, cancer cell
differentiation and apoptosis. Furthermore, these molecules
can inhibit angiogenesis and metastasis and enhance cell
sensitivity to chemotherapy [28]. Several HDACi are being
tested in phase II–III trials as reported in Table 3 and in-
clude both natural and synthetic compounds [29]. Vorino-
stat and romidepsin are the first agents approved by the
FDA and EMA for the treatment of progressive or recur-
rent cutaneous T cell lymphoma (CTCL) [30], while several
other molecules, listed in Table 2, are in the early phases of
clinical development [31].
Currently, several clinical trials are testing the use of a
different combination of DNMT and HDAC inhibitors,
together with cyclin-dependent kinase inhibitors (CDKi)
or proteasome inhibitors or engineered transcriptional
factors [32–36].
Another new concept derives from the observation
that patients with the same disease may have different
symptoms and may not or only poorly respond to con-
ventional therapy. This brings about the concept of “per-
sonalized medicine,” also known as “precision medicine.”
This new branch of medicine, basically, encompasses the
tailoring of medical treatment on the basis of individual
characteristics, needs, and preferences of each patient, in
order to improve outcomes [37]. As very prematurely
stated by Hippocrates “It’s far more important to know
what person the disease has than what disease the per-
son has,” introducing for the first time the idea of the
“individuality” of disease and the importance of prescrip-
tion of “different” medicines to “different” patients.
In this contest, gene-expression profiling and genomic
studies represent potential tools for improving patient
management through their classification into clinically
relevant subtypes for prevision therapy [38]. Although
FDA has already approved some expression profiling plat-
forms for clinical use, strong claims cannot yet be made
about the clinical value of these signatures. Other import-
ant technological platforms are being developed to analyze
epigenetic changes in DNA, microRNAs, and proteins.
These allow to identify biomarkers for individual’s classifi-
cation into subpopulations that differ in their susceptibility
to a particular disease or in their response to a specific
treatment. Furthermore, it is important to highlight that,
although a few drugs used for personalized medicine have
been approved by FDA, various challenges still exist, given
the observation that each patient is unique and, similarly,
displays a unique epigenomic signature.
Epigenetic in stem cell research
Access to unlimited numbers of specific cell types repre-
sents the major goal in regenerative medicine. Recent ad-
vances in the stem cell field led to the production of iPSCs
that were generated in 2006 through genetic reprogram-
ming of adult somatic cells. Following these studies, sev-
eral researchers succeeded in producing iPSCs. However,
although various methodologies have been established for
Table 3 List of HDACs and their current status in clinical trials
Group Example Current status
Short-chain fatty acid Valproic acid Phase II CT
Phenyl butyrate Phase II CT
Pivanex Phase II CT
Hydroxamic acids Vorinostat FDA approved
Panobinostat Phase III CT
Belinostat Phase II CT
Abexinostat Phase II CT
Resminostat Phase II CT
Givinostat Phase II CT
Dacinostat Phase II CT
Pracinostat Phase II CT
Cyclic tetrapeptide Romidepsin FDA approved
Apicidin Phase II CT
Trapoxin A No data
Benzamide Mocetinostat Phase II CT
Entinostat Phase II CT
Rocilinostat Phase II CT
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their derivation, the efficiency of iPSC induction remains
low. Furthermore, the integration of transgenes severely
limits their use in clinical studies [39]. Therefore, several re-
programming technologies that increase efficiency, acceler-
ate kinetics, and eliminate the use of virus-mediated gene
have been developed. Different approaches have been tested,
from virus-free [40–42] to removable PiggyBac transposons
[43], minicircle systems [44], and episomal systems [45].
Nevertheless, evidence persists demonstrating the problems
related to residual exogenous DNA and chromosomal dis-
ruptions that result in harmful genetic alterations [46].
In order to circumvent these limits related to low effi-
ciency and the introduction of exogenous transcription
factors, small-molecule compounds have been used to
modulate the epigenetic state increasing reprogramming
efficiency, by inhibiting and activating, in reversible way,
specific signaling pathways [47–50].
Huangfu et al. reported that the HDAC inhibitor, val-
proic acid (VPA), not only improves reprogramming effi-
ciency by more than 100-fold but also enables efficient
induction of human and murine iPSCs, without intro-
duction of the myelocytomatosis oncogene (c-Myc) [47].
Subsequently, it was demonstrated that murine embry-
onic and adult fibroblasts could be reprogrammed by
stimulating cells with a specific chemical combination of
VPA, CHIR99021, 616452, and tranylcypromine (TCP), in
the presence of a single transcription factor, POU domain,
class 5, transcription factor 1 (Oct-4), without the use of
transgenes for SRY (sex-determining region Y)-box 2
(Sox2), Kruppel-like factor 4 (gut) (Klf4), and c-Myc [48].
A recent study also reveals that endogenous pluripotency
program can be re-activated through the use of small mole-
cules that modulate molecular pathways nonspecifically re-
lated to pluripotency, without the introduction of exogenous
genes. In that report, Hou et al. generated iPSCs from
murine somatic cells at a frequency up to 0.2%, using a
combination of seven small-molecule compounds, namely
VPA, CHIR99021, 616452, TCP, forskolin (FSK), 2-methyl-
5-hydroxytryptamine (2-Me-5HT), and D4476 [50]. In line
with these findings, Moschidou et al. demonstrated that the
use of VPA in combination with a low growth factor
medium (embryonic stem cell (ESC) medium) is able to re-
vert 82% of amniotic fluid cells into a pluripotent state that
shares transcriptome identity with ESC and ability to form
embryoid bodies (EB) and teratomas, as well as to differenti-
ate into cell lineages deriving from all the three germ layers
[51]. Similarly, endogenous pluripotency transcription factor
genes were re-activated in adult human dermal fibroblasts
using VPA, in the absence of any transgenes [52].
Although the exact mechanisms underlying iPSC gener-
ation still remain to be elucidated, these results suggest
that epigenetic modifiers improve cell reprogramming al-
tering chromatin structure and directly modulating the
epigenetic enzymes. These events possibly drive cells to a
more permissive state that allow changes in the epige-
nome, activating specific signaling pathways that influence
cell fate during reprogramming processes.
Altogether, the data obtained represent a significant
progress in cell reprogramming technology, with new
approaches that avoid the use of retroviral and/or lenti-
viral vectors and the insertion of transgenes.
Epigenetic and direct cell conversion: a new alternative
In recent years, several protocols that avoid the use of vir-
ally or non-virally introduced exogenous factors as well as
the establishment of a stable pluripotent state have been
developed. These new approaches involve the use of small
molecules and epigenetic modifiers in order to directly
convert an adult mature cell into another differentiated
cell type (Fig. 1).
Fig. 1 Schematic representation of epigenetic conversion experiments
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The first paper reporting the ability of a small molecule
to induce a de-differentiation in murine C2C12 myoblasts
was published in 2004 [53]. In these experiments, cells
were initially treated with a library of 50,000 small mole-
cules for 4 days, with the final goal of identifying target
compounds that can induce de-differentiation. The results
obtained demonstrated that reversine, a 2,6-disubstituted
purine, was able to increase cell plasticity, inducing lineage-
committed myoblasts to become multipotent mesenchymal
progenitor cells. The activity of this molecule was subse-
quently tested in several type of cells, including 3T3E1 os-
teoblasts [54], human primary skeletal myoblasts [54], and
murine and human dermal fibroblasts [55], confirming the
induction of an increased plasticity in treated cells.
More recent experiments demonstrated that a brief ex-
posure to a demethylating agent can push cells to a less
committed state, increasing their plasticity for a short win-
dow of time sufficient to re-address cells towards a differ-
ent cell type [2–7]. The starting hypothesis was that the
processes associated with differentiation are driven by sev-
eral mechanisms. Among these, DNA methylation plays a
fundamental role during both early embryonic develop-
ment and cell lineage specification, causing silencing of
large fraction of the genome and subsequent expression of
gene essential for the maintenance of the differentiated
and tissue-specific phenotype. Based on this, 5-azacytidine
(5-aza-CR), a well-characterized DNMT inhibitor, was se-
lected in order to remove the epigenetic “blocks” that are
responsible for tissue specification [3–5, 7]. This drug is a
chemical analog of cytosine, it can be incorporated into
DNA and RNA, causing an increased effect in resting as
well as in dividing cells, and it is known to be a direct in-
hibitor of methylation in newly synthesized DNA by
blocking DNMT function [56]. These features give 5-aza-
CR the ability to induce DNA hypomethylation, modify
gene expression, and reactivate the transcription of silent
genes in eukaryotic cells [57–62].
In agreement with these findings, human mesenchy-
mal stromal cells (MSC) and skin fibroblasts were trans-
formed into hematopoietic cells after an incubation with
5-aza-CR, granulocyte-macrophage colony-stimulating
factor (GM-CSF), and stem cell factor (SCF) [2].
Moreover, our laboratory demonstrated that adult skin
fibroblasts and granulosa cells, derived from different
species, namely human [3, 5], porcine [4], and dog [63],
can be converted into a different cell type, belonging to
the same embryonic layer or even to a different one.
The “highly permissive state” enriched by cells, after 5-
aza-CR exposure, was paralleled by decrease in global
DNA methylation and was accompanied by significant
changes in cell phenotype and a specific and consistent
gene regulatory response. Indeed, after demethylating agent
treatment, both cell types used in the experiments, adult
skin fibroblasts and granulosa cells, exhibited reduced
dimensions, increased nuclear volume, and highly de-
condensed chromatin [3–5]. These observations are in
agreement with the morphological features distinctive of
highly plastic cells that contain more loosely packed chro-
matin than their differentiated counterparts, in order to
maintain genes in a potentially open state and prepare
them for future expression [64]. Preliminary data obtained
in our laboratory with next-generation sequencing analysis
of 5-aza-CR exposed cells indicate changes of several
pathways, mostly related to histone transcription and cell
adhesion. This suggests the possibility that, beside the
well-known effect on DNMTs and cell methylation, 5-aza-
CR action on cell plasticity and differentiation may take
place through alternative mechanisms that require the in-
volvement of novel cellular targets (manuscript under re-
vision). Notably, this process is completely reversible and
does not show toxic effects, since cells returned to their
standard culture medium, reverted to their original pheno-
type within a few days. The absence of genotoxic effects is
further supported by cytogenetic analysis showing that
5-aza-CR-treated cells maintained a normal karyotype
throughout the entire length of the experiments [3–5].
We also demonstrated that, once cells entered into the
higher plasticity window, they could easily be directed
towards a different phenotype if they were exposed to
specific differentiation stimuli.
In particular, skin fibroblasts of human, porcine, and ca-
nine origin were converted towards the pancreatic lineage,
using a three-step induction protocol. This allowed cells to
transit from the early endodermic and pancreatic differenti-
ation stage to mature endocrine cells. At the end of the epi-
genetic conversion, cells formed large three-dimensional
spherical structures, reminiscent of in vitro-cultured pan-
creatic islets. They expressed the main hormones and glu-
cose sensor genes specific of pancreatic tissue and were
able to actively release of C-peptide and insulin after expos-
ure to 20 mM glucose, showing a dynamic response similar
to pancreatic β cells, in which changes in ambient glucose
represent the primary and physiological stimulus for insulin
secretion. Furthermore, cell functionality was also demon-
strated in vivo using immunodeficient severe combined
immunodeficiency (SCID) mice whose β cells had been se-
lectively destroyed with streptozotocin, demonstrating con-
verted cell ability to restore normo-glycaemia and stably
maintain mice glucose levels [3, 4].
The possibility to apply epigenetic conversion to different
cell types has been demonstrated using granulosa cells as
starting cell population and converting them into muscle
cells through the use of 5-aza-CR followed by a 15-day cul-
ture with human recombinant vascular endothelial growth
factor (VEGF) [5]. At the end of the conversion, over 80%
of granulosa cells change the original phenotype and
become elongated and multinucleated. These morpho-
logical changes were paralleled by the up-regulation of
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muscle-specific genes, such as desmin (DES), myosin heavy
chain (MHC), and myogenic differentiation (MYOD). In
contrast, markers distinctive of granulosa cells (cytokeratin
17 (KRT17), hyaluronan synthase 2 (HAS2), gremlin 1
(GREM1), and pentraxin 3 (PTX3)) were turned down.
In agreement with our results, the demethylating agent
5-aza-CR was also demonstrated to convert human fore-
skin fibroblasts into neural progenitor-like cells [6]. At the
end of the 14-day neural conversion, cells down-regulated
fibroblast specific protein 1 (FSP1) and expressed high
levels of neural progenitor markers, namely SOX2, NES-
TIN, PAX6, EN1, LMX1A, and WNT1. Molecular switch
was accompanied by morphological changes, with cells
becoming smaller, acquiring radial arrangement, and pro-
ducing neurosphere-like aggregates.
Cheng et al. reported that it is possible to convert hu-
man and murine fibroblasts into proliferating chemical-
induced neural progenitor cells (ciNPC), using a cocktail
containing inhibitors of histone deacetylation, glycogen
synthase kinase, and TGF-β pathway under physiological
hypoxic conditions (5% O2) [65].
Furthermore, recent experiments described the possibility
to epigenetically convert human skin fibroblasts into ma-
ture Schwann cells through the use of the HDAC inhibitor
VPA [66]. In that work, cells were stimulated with a two-
step neural induction protocol, in order to obtain a transi-
ent population of proliferating neural precursors and, sub-
sequently, terminally differentiated Schwann cells (iSCs),
that showed neuro-supportive and myelination capacity,
and expressed proteins specific of the peripheral nervous
system.
Conclusions
Altogether, the results accumulated during the last years
have paved the way to the use of small molecules for
personalized medicine, drug targeting, and the induction
of changes in cell fate. Some of these molecules have been
already approved for patient’s treatment and are currently
used for the cure of disease caused be epigenetic aberra-
tions, while other chemical compounds are tested in sev-
eral clinical trials. In this context, various challenges still
exist given the observation that each patient is unique and
displays a unique epigenomic signature, and more studies
are indeed in order to develop epigenetic biomarkers,
technologies, and tools to classify individuals into subpop-
ulations that differ in their susceptibility to a particular
disease or in their response to a specific treatment.
Epigenetic modifiers are also been used to replace TFs for
iPSC generation. Indeed, mouse and human iPSCs have
been generated using a small-molecule-based reprogram-
ming protocol, without the use of genetic material. How-
ever, although these cells may represent a promising stem
cell source, it is important to highlight that the induction of
a stable pluripotent state, and the deriving cell instability,
severely limits their use in regenerative medicine.
The new proposed method of epigenetic cell conversion
demonstrated that it is possible to dynamically interact
with cell genotype and phenotype through the use of epi-
genetic modifiers. This approach allows to directly convert
a terminally differentiated cells into a different cell type,
without the use of transgenes, and increase cell plasticity
only for a short and transient period, and avoid the induc-
tion of a stable pluripotent state. This makes epigenetic
conversion a very promising tool for regenerative medi-
cine. Furthermore, the results obtained indicate that this
protocol is robust since it was successfully applied to dif-
ferent cell types as well as in several species [3–5].
All this evidences support for the importance of epi-
genetic related approaches widen their application both
to human as well as to veterinary regenerative medicine
for the cure of several and diverse degenerative diseases.
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